SGK
DGX icon

Steigerwald Gordon & Koch’s Quest Diagnostics DGX Stock Holding History

Steigerwald Gordon & Koch’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.1K Buy
345
+100
+41% +$19.6K 0.01% 257
2026
Q1 		$48K Hold
245
– – ﹤0.01% 308
2025
Q4 		$42.5K Hold
245
– – ﹤0.01% 338
2025
Q3 		$46.7K Buy
+245
New +$43.5K ﹤0.01% 311

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Steigerwald Gordon & Koch's DGX Position: Q2 2026 in Review

Steigerwald Gordon & Koch increased its Quest Diagnostics (DGX) stake by 41% in Q2 2026, buying an estimated $19.6K and bringing the position to 345 shares worth $73.1K. The position accounts for 0.01% of the portfolio, ranked #257.

Steigerwald Gordon & Koch first reported a position in DGX in Q3 2025 and has held it in 4 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Steigerwald Gordon & Koch held 345 shares of Quest Diagnostics worth $73.1K as of Q2 2026.
  • Steigerwald Gordon & Koch bought 100 Quest Diagnostics shares in Q2 2026, an estimated $19.6K.
  • Quest Diagnostics made up 0.01% of Steigerwald Gordon & Koch's portfolio in Q2 2026, its #257 holding.
  • Steigerwald Gordon & Koch first reported a position in Quest Diagnostics in Q3 2025 and has held it in 4 quarters since.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Steigerwald Gordon & Koch's 13F filing for Q2 2026, filed 23 Jul 2026.